Yunxin Wang

Yunxin Wang

Auto-generated profile, based on publicly available information

Yunxin Wang

Department of Radiation Oncology The Second Affiliated Hospital of Dalian Medical University Dalian China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2024 in Cancer Reports
Verified
Journal Article
Open access
YWYunxin Wang
Yunxin Wang
YMYuhong Ma
Yuhong Ma
LZLijuan Zou
Lijuan Zou
HLHongwei Lei
Hongwei Lei
YTYun Teng
Yun Teng
HZHaichen Zhang
Haichen Zhang
Background: The study aimed to assess the efficacy and safety of 125I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy. This meta‐analysis was registered in PROSPERO. We looked up relevant studies in the databases of CNKI, Wanfang, CBM, PubMed, Embase, Cochrane Library, and Web of Science. The endpoint measures include the objective response rate, disease control rate, progression‐free survival, overall survival, and adverse events.Recent Fidings: The meta‐analysis included six studies and a total of 246 patients. The pooled ORR of tumor response was 63%, and the DCR was 87%. The median PFS was 9.09 months, and the median OS was 13.46 months. The incidence of adverse events of Grade ≥III was 6%.Conclusion: In conclusion, this meta‐analysis confirmed that 125I seed implantation has a good local control rate and high safety in the treatment of pelvic recurrent cervical cancer following radiotherapy, and can be used as a remedial treatment for pelvic recurrent cervical cancer following radiotherapy to prolong the survival time of patients.Trial Registration: PROSPERO: CRD42023423857

1 November 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ZLZ. Liu
Z. Liu
TWT. Wang
T. Wang
KZK. Zhang
K. Zhang
YWY. Wang
Y. Wang
LWLibo Wei
Libo Wei
LLL. Liu
L. Liu